Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) dropped 14.5% during mid-day trading on Tuesday . The company traded as low as C$0.27 and last traded at C$0.27. Approximately 438,482 shares traded hands during trading, a decline of 36% from the average daily volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Performance
The stock has a fifty day moving average of C$0.11 and a 200-day moving average of C$0.08. The company has a market cap of C$23.09 million, a PE ratio of -13.25 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Transports Are Trending Higher: It’s a Golden Time to Buy More
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- A Hidden Winner in Manufacturing and Energy Set for a Breakout
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Beyond Rigetti: Top 3 Quantum Computing Stock Picks
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
